Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
The REWIND trial, targeting cardiovascular events in T2DM participants without previous cardiovascular history, found that dulaglutide reduced cardiovascular outcomes, and was well tolerated [61]
Our guide covers injection site reactions, metabolic changes, and practical management strategies
Ideal candidates include individuals struggling with obesity, metabolic imbalance, or persistent weight challenges resistant to conventional diet and exercise efforts
These drugs are not currently on the American Red Cross medication deferral list, provided you meet all other health requirements and feel well on the day of your appointment
Probes in the core region allow for a more reliable identification of subtypes 1a, 1b and 6c-l than the previous version of this assay
